Skip to main content
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. logo

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. — Investor Relations & Filings

Ticker · 2196 ISIN · CNE100001M79 HKEX Manufacturing
Open in API
Filings indexed 4,449 across all filing types
Latest filing 2026-05-29 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 2196

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

http://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven healthcare industry group operating across pharmaceuticals, medical devices, medical diagnosis, and healthcare services. The company focuses on therapeutic areas including oncology, cardiovascular, central nervous system, and metabolism, prioritizing technological advancement in small molecule development, antibody/ADC platforms, and cell therapies. Key products include Yikeda®, China's first approved CAR-T cell therapy product, and innovative biologics such as the anti-PD-1 monoclonal antibody Hanszhuang®. Fosun Pharma is a significant global health contributor via Artesun® (Artesunate injection), a WHO-recommended first-line treatment for severe malaria. The company also markets biosimilars, including Hanquyou® (Trastuzumab), which achieved dual approval in China and Europe, and distributes high-value medical devices, such as the Da Vinci surgical robot.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 90% confidence The document is extremely brief (under 250 characters) and merely states that an announcement has been published elsewhere on the issuer’s website. It contains no substantive financial data or detailed content itself but simply notifies readers that a publication has occurred. Under the “menu vs meal” rule, this is a report publication announcement rather than the full report, so it is classified as RPA.
2026-05-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 98% confidence The document is extremely brief and merely informs readers that an announcement has been published on the issuer’s website (in the Chinese section) without containing any substantive report content or financial data. It is an announcement about the publication of a report rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA).
2026-05-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 85% confidence The document is extremely short (under 250 characters) and merely states that an announcement has been published in the Chinese section of the issuer’s website. It contains no substantive content of any report, only a notice that a report or announcement is available elsewhere. This matches the definition of a Report Publication Announcement (RPA).
2026-05-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 85% confidence The document is extremely short (242 characters) and contains no substantive content other than notifying that an announcement has been published elsewhere. It does not include any financial data, meeting results, or management changes. This matches a Report Publication Announcement (RPA) since it merely states that a report/announcement has been released and may be available on the website.
2026-05-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 60% confidence The document is extremely short (under 5,000 characters) and merely notifies that an announcement has been published on the issuer’s website (Chinese section) without containing substantive financial or report content. Per the “menu vs meal” rule, this is an announcement of a report/publication rather than the report itself. Thus it should be classified as a Report Publication Announcement (RPA).
2026-05-26 English
Overseas Regulatory Announcement - Announcement in Relation to the Approval for Drug Registration of a Subsidiary
Regulatory Filings Classification · 20% confidence The document is an official announcement under Rule 13.10B of the Hong Kong Listing Rules regarding the drug registration approval for a subsidiary. It does not contain financial results, board changes, share transactions, or call transcripts. It is a general regulatory announcement/compliance filing, which fits the Regulatory Filings (RNS) category.
2026-05-21 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.